Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

The introduction of targeted therapy against CD20(+) with the monoclonal antibody rituximab has dramatically improved the survival of B-cell non-Hodgkin lymphoma including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. Unfortunately, CLL remains incurable with chemoimmunotherapy, wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerquozzi, Sonia, Owen, Carolyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337412/
https://www.ncbi.nlm.nih.gov/pubmed/25733804
http://dx.doi.org/10.2147/BTT.S61600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337412/
https://www.ncbi.nlm.nih.gov/pubmed/25733804
http://dx.doi.org/10.2147/BTT.S61600

Ejemplares similares